Analysts Expect Infinity Pharmaceuticals Inc. (NASDAQ:INFI) Will Announce Earnings of -$0.21 Per Share

Share on StockTwits

Equities analysts predict that Infinity Pharmaceuticals Inc. (NASDAQ:INFI) will post ($0.21) earnings per share for the current fiscal quarter, according to Zacks. Three analysts have issued estimates for Infinity Pharmaceuticals’ earnings, with the highest EPS estimate coming in at ($0.19) and the lowest estimate coming in at ($0.22). Infinity Pharmaceuticals posted earnings per share of ($0.14) in the same quarter last year, which suggests a negative year over year growth rate of 50%. The company is scheduled to issue its next quarterly earnings report on Thursday, March 12th.

On average, analysts expect that Infinity Pharmaceuticals will report full-year earnings of ($0.83) per share for the current fiscal year, with EPS estimates ranging from ($0.85) to ($0.81). For the next year, analysts expect that the company will post earnings of ($0.90) per share, with EPS estimates ranging from ($0.96) to ($0.83). Zacks Investment Research’s earnings per share averages are a mean average based on a survey of sell-side analysts that cover Infinity Pharmaceuticals.

Infinity Pharmaceuticals (NASDAQ:INFI) last issued its quarterly earnings data on Wednesday, October 30th. The biotechnology company reported ($0.20) EPS for the quarter, missing the consensus estimate of ($0.18) by ($0.02). Infinity Pharmaceuticals had a negative net margin of 1,519.91% and a negative return on equity of 125.37%. The business had revenue of $0.34 million during the quarter, compared to analyst estimates of $0.85 million.

Separately, B. Riley started coverage on Infinity Pharmaceuticals in a report on Monday, November 18th. They issued a “buy” rating and a $3.50 price objective on the stock. Two research analysts have rated the stock with a hold rating and three have assigned a buy rating to the stock. The stock currently has an average rating of “Buy” and a consensus price target of $2.83.

Shares of INFI opened at $1.17 on Wednesday. The company has a current ratio of 6.22, a quick ratio of 6.22 and a debt-to-equity ratio of 0.11. Infinity Pharmaceuticals has a 12 month low of $0.82 and a 12 month high of $1.95. The stock’s 50 day moving average is $1.15 and its two-hundred day moving average is $1.23. The firm has a market cap of $66.72 million, a P/E ratio of -5.85 and a beta of 1.82.

Several large investors have recently modified their holdings of INFI. Renaissance Technologies LLC boosted its stake in shares of Infinity Pharmaceuticals by 12.4% in the second quarter. Renaissance Technologies LLC now owns 1,002,006 shares of the biotechnology company’s stock worth $1,804,000 after acquiring an additional 110,806 shares during the last quarter. Parametric Portfolio Associates LLC acquired a new stake in shares of Infinity Pharmaceuticals in the second quarter worth approximately $76,000. Evercore Wealth Management LLC boosted its stake in shares of Infinity Pharmaceuticals by 20.7% in the second quarter. Evercore Wealth Management LLC now owns 143,138 shares of the biotechnology company’s stock worth $258,000 after acquiring an additional 24,553 shares during the last quarter. Finally, Jacobs Levy Equity Management Inc. boosted its stake in shares of Infinity Pharmaceuticals by 5.0% in the second quarter. Jacobs Levy Equity Management Inc. now owns 201,438 shares of the biotechnology company’s stock worth $363,000 after acquiring an additional 9,511 shares during the last quarter. 51.46% of the stock is currently owned by hedge funds and other institutional investors.

About Infinity Pharmaceuticals

Infinity Pharmaceuticals, Inc, a biopharmaceutical company, develops medicines for people with cancer in the United States. Its product candidate is IPI-549, an orally administered clinical-stage immuno-oncology product candidate that inhibits the enzyme phosphoinositide-3-kinase-gamma (PI3K-gamma), which is in Phase 1/1b clinical study.

Further Reading: What is the S&P/TSX Index?

Get a free copy of the Zacks research report on Infinity Pharmaceuticals (INFI)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Infinity Pharmaceuticals (NASDAQ:INFI)

Receive News & Ratings for Infinity Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Infinity Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.